BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34496819)

  • 1. Sequential immune-targeted surgical therapy resulted in disease-free survival in a case with advanced renal cell carcinoma.
    Nishimura K; Miura N; Sugihara N; Funaki K; Koyama K; Sawada Y; Noda T; Fukumoto T; Miyauchi Y; Kikugawa T; Saika T; Matsumura M; Hashine K; Taniwaki M
    BMC Urol; 2021 Sep; 21(1):124. PubMed ID: 34496819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
    Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
    J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
    Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N
    Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE].
    Tsukahara S; Nagatomi Y; Otsubo S; Hasegawa S
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):32-35. PubMed ID: 31956216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
    Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
    Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
    Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
    Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G; Schmidt L; Tolat P; Riese M; Kilari D
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma.
    Adler AI; Brooke A; Elsada A; Landells L
    Lancet Oncol; 2019 Jul; 20(7):904-905. PubMed ID: 31103427
    [No Abstract]   [Full Text] [Related]  

  • 9. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
    Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
    Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Targeted Molecular Therapy Before Renal Surgery.
    Dey S; Peabody HN; Noyes SL; Lane BR
    Urol Clin North Am; 2017 May; 44(2):289-303. PubMed ID: 28411920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
    Epaillard N; Simonaggio A; Elaidi R; Azzouz F; Braychenko E; Thibault C; Sun CM; Moreira M; Oudard S; Vano YA
    Bull Cancer; 2020 Jun; 107(5S):eS22-eS27. PubMed ID: 32620212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
    Carlo MI; Attalla K; Mazaheri Y; Gupta S; Yildirim O; Murray SJ; Coskey DT; Kotecha R; Lee CH; Feldman DR; Russo P; Patil S; Motzer RJ; Coleman JA; Durack JC; Chen YB; Akin O; Ari Hakimi A; Voss MH
    Eur Urol; 2022 Jun; 81(6):570-573. PubMed ID: 35183395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [RENAL CELL CARCINOMA METASTASIS TO BLADDER DURING MOLECULAR TARGETED THERAPY WITH PAZOPANIB: REPORT OF TWO CASES].
    Maruo K; Takahashi A; Tabata H; Takayanagi A; Takagi Y
    Nihon Hinyokika Gakkai Zasshi; 2020; 111(2):58-61. PubMed ID: 33883361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
    Hashimoto M; Nakayama T; Fujimoto S; Inoguchi S; Nishimoto M; Kikuchi T; Adomi S; Banno E; De Velasco MA; Saito Y; Shimizu N; Mori Y; Minami T; Fujita K; Nozawa M; Nose K; Yoshimura K; Uemura H
    Anticancer Drugs; 2022 Jan; 33(1):e818-e821. PubMed ID: 34486537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
    Cao X; Tang D; Ratto B; Poole A; Ravichandran S; Jin L; Gao W; Swallow E; Vogelzang NJ
    Clin Genitourin Cancer; 2020 Feb; 18(1):e37-e45. PubMed ID: 31727510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
    Patel HD; Puligandla M; Shuch BM; Leibovich BC; Kapoor A; Master VA; Drake CG; Heng DY; Lara PN; Choueiri TK; Maskens D; Singer EA; Eggener SE; Svatek RS; Stadler WM; Cole S; Signoretti S; Gupta RT; Michaelson MD; McDermott DF; Cella D; Wagner LI; Haas NB; Carducci MA; Harshman LC; Allaf ME
    Future Oncol; 2019 May; 15(15):1683-1695. PubMed ID: 30968729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
    N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
    Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
    J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
    Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
    Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.